Compare · DFTX vs IMCC
DFTX vs IMCC
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and IM Cannabis Corp. (IMCC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and IMCC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.51B, about 1363.0x IMCC ($1.8M).
- Over the past year, DFTX is up 196.5% and IMCC is down 88.3% - DFTX leads by 284.8 points.
- DFTX has been more active in the news (3 items in the past 4 weeks vs 2 for IMCC).
- DFTX has more recent analyst coverage (4 ratings vs 3 for IMCC).
PerformanceDFTX+191.58%IMCC-88.34%
2025-06-10+0.00%2026-06-08
- Company
- Definium Therapeutics Inc.
- IM Cannabis Corp.
- Price
- $23.02-2.29%
- $0.28-3.08%
- Market cap
- $2.51B
- $1.8M
- 1M return
- -0.95%
- +6.42%
- 1Y return
- +196.46%
- -88.34%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 2
- Recent ratings
- 4
- 3
IMCC
IM Cannabis Corp.
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest IMCC
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Corp. Announces First Quarter 2026 Financial Results
- SEC Form 6-K filed by IM Cannabis Corp.
- IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings
- SEC Form 6-K filed by IM Cannabis Corp.
- IMC Announces Receipt of Nasdaq Minimum Bid Price Notification
- SEC Form 6-K filed by IM Cannabis Corp.
- SEC Form 6-K filed by IM Cannabis Corp.